The key facts about the bioproducion sector

👉 IQVIA analyzes trends in the biotech sector

In its report Global Trends in R&D 2025: Progress in Recapturing Innovation in Biopharma Innovation, IQVIA reviews the major trends in the biotech sector, marked in particular by a 17% jump in R&D investment by major pharmaceutical companies, to $190 billion last year. With regard to biomanufacturing, the report notes the growth of radiopharmaceuticals and RNA therapies, which require specific production infrastructures. It also stresses the growing importance of clinical trials in China, with a strengthening of the complete value chain in China. Another trend is the growing role of artificial intelligence in the sector. Numerous strategic partnerships have indeed been signed in recent years between laboratories and AI companies, to accelerate and streamline the design of therapeutic proteins, bispecific antibodies, or peptides.

👉 The European Commission sets out its ambitions for biomanufacturing

Biomanufacturing will be high on the agenda of the Horizon Europe program this year, with the ambition of strengthening the continent's industrial innovation. According to a roadmap unveiled by the European Commission, targeted projects include biosynthesis, precision fermentation and the cultivation of genetically modified micro-organisms to produce bioactive compounds and food nutrients. The program also plans to facilitate access to pilot infrastructures via initiatives such as Pilots4U, a network of open-access pilot and demonstration infrastructures for the European bioeconomy, and Copilot, a project aimed at improving access to pilot platforms for the industrialization of biotechnological processes.

👉 FDA budget cuts slow biomedical development

Massive delays at the FDA are disrupting the clinical trials of many biotechs, laments the Wall Street Journal, pointing the blame at layoffs ordered by the US administration. The loss of 3,500 employees, including top drug and vaccine executives, has disrupted the agency, which is now struggling to perform key functions, including validating trial protocols, dealing with companies and approving new drugs. Dozens of executives, patient advocates and investors have sent a letter to Senator Bill Cassidy, Chairman of the Senate Health Committee, asking him to “identify areas where the FDA's capabilities have been affected in order to quickly preserve and restore its essential functions”.